

I'm a planner who likes having things in order. I know myself.

I know the **KRAS G12C biomarker** is driving my non-small cell lung cancer (NSCLC) and there's a treatment option designed for my biomarker."¹

Patient testimonial represents individual's experience with LUMAKRAS®. Results may vary.



—Laurie,
current LUMAKRAS® patient

Did you know? LUMAKRAS® is the first once-daily oral treatment for people living with NSCLC

that has spread to other parts of the body, or cannot be removed by surgery, and whose tumor is KRAS G12C positive, and who have received at least one prior treatment.¹ It's not chemotherapy.^{1,2}

What is LUMAKRAS®?

LUMAKRAS® is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC):

- that has spread to other parts of the body or cannot be removed by surgery, **and**
- whose tumor has an abnormal KRAS G12C gene, **and**
- who have received at least one prior treatment for their cancer.

Your healthcare provider will perform a test to make sure that LUMAKRAS® is right for you. It is not known if LUMAKRAS® is safe and effective in children.

Important Safety Information

What should I tell my healthcare provider before taking LUMAKRAS®?

- Before taking LUMAKRAS®, tell your healthcare provider about all your medical conditions, including if you:
 - o have liver problems.
 - o have lung or breathing problems other than lung cancer.
 - o are pregnant or plan to become pregnant. It is not known if LUMAKRAS® will harm your unborn baby.
 - o are breastfeeding or plan to breastfeed. It is not known if LUMAKRAS® passes into your breast milk. Do not breastfeed during treatment with LUMAKRAS® and for 1 week after the last dose.
- Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, dietary and herbal supplements. LUMAKRAS® can affect the way some other medicines work, and some other medicines can affect the way LUMAKRAS® works.
- Especially tell your healthcare provider if you take antacid medicines, including Proton Pump Inhibitor (PPI) medicines or H₂ blockers during treatment with LUMAKRAS®. Ask your healthcare provider if you are not sure.

Please see additional important safety information throughout.

ONCE-DAILY ORAL

LUMAKRAS®
(sotorasib) 120 mg tablets
320 mg tablets

Why is it important to test for and know my biomarker status?




Not an actual patient

It begins with KRAS.



What is KRAS? It is a protein that we all have in our bodies. Proteins are required for the structure and function of the body's cells, tissues, and organs.³



The KRAS protein works like an on/off switch, relaying messages that tell cells when to grow and when to stop growing.⁴




One of the most common NSCLC biomarkers is KRAS G12C.⁵

What is a KRAS G12C mutation?



KRAS G12C is a mutation of the KRAS protein. Sometimes a protein can become mutated (altered) and function abnormally.⁴



KRAS G12C causes the on/off switch to get stuck in the "on" position, leading to continuous and uncontrollable cell growth that can form tumors.⁶

Important Safety Information (Continued)

LUMAKRAS® may cause serious side effects, including:

- **Liver Problems:** LUMAKRAS® may cause abnormal liver blood test results. Your healthcare provider should do blood tests before starting and during treatment with LUMAKRAS® to check your liver function. Tell your healthcare provider right away if you get any signs or symptoms of liver problems, including: your skin or the white part of your eyes turns yellow (jaundice), dark or "tea-colored" urine, light-colored stools (bowel movements), tiredness or weakness, nausea or vomiting, bleeding or bruising, loss of appetite, and pain, aching, or tenderness on the right side of your stomach-area (abdomen).

Please see additional important safety information throughout.

ONCE-DAILY ORAL

LUMAKRAS®
(sotorasib) 120 mg tablets
320 mg tablets

How can biomarker testing help me with my NSCLC treatment?



Approximately **1 in 8 people** with NSCLC has KRAS G12C.⁵



If you have the KRAS G12C biomarker, it could mean there's a targeted treatment option specially designed for your type of lung cancer.¹

The only way to know if you have KRAS G12C is by asking your doctor for a biomarker test.⁷



Once you know your biomarker status, it may help your doctor create a personalized treatment plan just for you.⁸

How will my doctor test for KRAS G12C?

- Your doctor can test you for the KRAS G12C biomarker by using a biopsy.^{2,8}
- A biopsy can be done by using either a tissue from the tumor (tissue biopsy) or a blood test (liquid biopsy).⁸
- Your doctor will determine which test is right for you.⁸

When you have your results, keep them with you for future reference and remember to bring them up with your doctor whenever you're discussing your treatment plan.⁸

Important Safety Information (Continued)

LUMAKRAS® may cause serious side effects, including:

- Lung or breathing problems: LUMAKRAS® may cause inflammation of the lungs that can lead to death. Tell your healthcare provider or get emergency medical help right away if you have new or worsening shortness of breath, cough, or fever.
- Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with LUMAKRAS® if you develop side effects.

Please see additional important safety information throughout.

ONCE-DAILY ORAL

LUMAKRAS®
(sotorasib) 120 mg tablets
320 mg tablets

About LUMAKRAS[®] (sotorasib)



Not an actual patient

ABOUT LUMAKRAS[®]

How does LUMAKRAS[®] work to treat NSCLC?

- LUMAKRAS[®] is the first oral treatment specifically designed for tumors with the KRAS G12C mutation.¹
- In tumors with the KRAS G12C mutation, the protein remains mostly in an “on” position, and cells are continuously forced to grow.⁶
- LUMAKRAS[®] targets the mutated KRAS protein and locks it in the “off” position. This may prevent tumor cell growth.²

**I know I like to have
all the information.
*I know myself.***

**Now I know how being KRAS G12C positive
may impact my NSCLC treatment plan.²**



Not an actual patient

**If your NSCLC is KRAS G12C positive and has been treated
with a prior therapy, ask your doctor if LUMAKRAS[®] may be
able to help.¹**

Important Safety Information (Continued)

The most common side effects

- The most common side effects of LUMAKRAS[®] include diarrhea, muscle or bone pain, nausea, tiredness, liver problems, cough, changes in liver function tests, and changes in certain blood tests.
- These are not all the possible side effects of LUMAKRAS[®].
Call your doctor for medical advice about side effects.

**Please see additional important safety
information throughout.**

ONCE-DAILY ORAL

LUMAKRAS[®]
(sotorasib) 120 mg tablets
320 mg tablets

How do I take LUMAKRAS® to treat my NSCLC?



Take LUMAKRAS® once daily by mouth with or without food.¹



The recommended dose of LUMAKRAS® is 960 mg (three 320 mg tablets or eight 120 mg tablets) taken once daily.²

- Take LUMAKRAS® exactly as your doctor tells you to take it. Do not change your dose or stop taking LUMAKRAS® unless your healthcare provider tells you to.¹
- Take your prescribed dose of LUMAKRAS® 1 time each day, at about the same time each day.¹

There are two different LUMAKRAS® tablets.

120 mg dose



Light yellow color
Oblong shape
Recommended daily dose: 8 pills²



320 mg dose



Beige color
Larger, oval shape
Recommended daily dose: 3 pills²



Please make sure you take the right number of pills and speak with your doctor if you have questions.

ONCE-DAILY ORAL

LUMAKRAS®
(sotorasib) 120 mg tablets
320 mg tablets

I know I'm a very determined person.

So I know I want a treatment that is designed for KRAS G12C positive NSCLC.

Not an actual patient



Important Safety Information (Continued)

What should I tell my healthcare provider before taking LUMAKRAS®?

- Before taking LUMAKRAS®, tell your healthcare provider about all your medical conditions, including if you:
 - o have liver problems.
 - o have lung or breathing problems other than lung cancer.
 - o are pregnant or plan to become pregnant. It is not known if LUMAKRAS® will harm your unborn baby.
 - o are breastfeeding or plan to breastfeed. It is not known if LUMAKRAS® passes into your breast milk. Do not breastfeed during treatment with LUMAKRAS® and for 1 week after the last dose.
- Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, dietary and herbal supplements. LUMAKRAS® can affect the way some other medicines work, and some other medicines can affect the way LUMAKRAS® works.
- Especially tell your healthcare provider if you take antacid medicines, including Proton Pump Inhibitor (PPI) medicines or H₂ blockers during treatment with LUMAKRAS®. Ask your healthcare provider if you are not sure.

Please see additional important safety information throughout.

ONCE-DAILY ORAL

LUMAKRAS®
(sotorasib) 120 mg tablets
320 mg tablets

How do I take LUMAKRAS® to treat my NSCLC? (Continued)

Swallow LUMAKRAS® tablets whole. Do not chew, crush, or split tablets.¹



If you cannot swallow LUMAKRAS® tablets whole¹:

- Disperse tablets in 120 mL (4 ounces) of non-carbonated, room-temperature water without crushing. No other liquids should be used.
- Stir or swirl the cup for about 3 minutes until tablets are dispersed into small pieces (the tablets will not completely dissolve) and drink immediately or within 2 hours. The appearance of the mixture may range from pale yellow to bright yellow.
- Swallow the tablet dispersion. Do not chew pieces of the tablet.
- Rinse the container with an additional 120mL (4 ounces) of water and drink.
- If the mixture is not consumed immediately, stir or swirl the mixture again to ensure that tablets are dispersed.

Important things to remember when taking LUMAKRAS®.

- If you take an antacid medicine such as Tums®, take LUMAKRAS® either 4 hours before or 10 hours after the antacid. Speak to your doctor if you are on PPIs or H₂ blockers.¹
- If you miss a dose of LUMAKRAS®, take the dose as soon as you remember. If it has been more than 6 hours, do not take the dose. Take your next dose at your regularly scheduled time the next day. Do not take 2 doses at the same time to make up for a missed dose.¹
- If you vomit after taking a dose of LUMAKRAS®, do not take an extra dose. Take your next dose at your regularly scheduled time the next day.¹

ONCE-DAILY ORAL

LUMAKRAS®
(sotorasib) 120 mg tablets
320 mg tablets

What are the possible serious side effects of LUMAKRAS®?



If you experience any of these side effects while taking LUMAKRAS®, you should call your doctor right away.¹

LUMAKRAS® may cause serious side effects, including¹:

- **Liver problems:** LUMAKRAS® may cause abnormal liver blood test results. Your healthcare provider should do blood tests before starting and during treatment with LUMAKRAS® to check your liver function.
 - Tell your healthcare provider right away if you get any signs or symptoms of liver problems, including: your skin or the white part of your eyes turns yellow (jaundice), dark or “tea-colored” urine, light-colored stools (bowel movements), tiredness or weakness, nausea or vomiting, bleeding or bruising, loss of appetite, and pain, aching, or tenderness on the right side of your stomach-area (abdomen).
- **Lung or breathing problems:** LUMAKRAS® can cause inflammation of the lungs that can lead to death. Tell your healthcare provider or get emergency medical help right away if you have new or worsening shortness of breath, cough or fever.

ONCE-DAILY ORAL

LUMAKRAS®
(sotorasib) 120 mg tablets
320 mg tablets

Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with LUMAKRAS® if you develop side effects.¹

What are the more common side effects of LUMAKRAS®?



When taking any medication, it's important to be aware of any side effects that you may experience.¹

The most common side effects of LUMAKRAS® include¹:

- Diarrhea
- Muscle or bone pain
- Nausea
- Tiredness
- Liver problems
- Cough
- Changes in liver function test and changes in certain other blood tests

These are not all the possible side effects of LUMAKRAS®. Call your doctor for medical advice about side effects. You may report side effects to the FDA at **1-800-FDA-1088**. You may also report side effects to Amgen at **1-800-772-6436** (1-800-77-AMGEN).¹

When taking any medication, it's important to be aware of any side effects that you may experience. Talk to your doctor immediately if you notice any side effects so they can make the appropriate decision about further treatment.¹

Please see additional important safety information throughout.

ONCE-DAILY ORAL

LUMAKRAS®
(sotorasib) 120 mg tablets
320 mg tablets

Support options

Deborah, real LUMAKRAS® patient,
and Jennifer, her sister and care partner



Support from Amgen

AMGEN® Support⁺

SUPPORT

Support from every angle

Want to chat? 1-888-427-7478 (1-888-4ASSIST), Monday–Friday,
9:00 AM to 8:00 PM EST

www.amgenassist360.com/patient

Amgen Nurse Navigators*

As a single point of contact, we'll guide you toward the resources that are most important to you. We're here to help you with the following**:

- Financial options for any insurance type
- Referrals to resources for day-to-day living
- Medication answers

*Amgen Nurse Navigators are only available to patients that are prescribed certain products. Nurse Navigators are there to support, not replace, your treatment plan, and do not provide medical advice, nursing or case management services. Patients should always consult their doctor regarding medical decisions or treatment concerns.

**Resources include referrals to independent, nonprofit patient assistance programs.

Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofit's criteria. Amgen has no control over these programs and provides referrals as a courtesy only.

ONCE-DAILY ORAL

LUMAKRAS®
(sotorasib) 120 mg tablets
320 mg tablets

If you need help paying for LUMAKRAS®

AMGEN® Support⁺ | Co-Pay Program

Helping eligible patients save on out-of-pocket costs

The Amgen SupportPlus Co-Pay Program is here to help eligible commercially insured patients pay for their out-of-pocket prescription costs.



- Pay as little as **\$0 out-of-pocket** for each dose or cycle (excluding Prolia® and EVENITY®)*
- Can be applied to deductible, co-insurance, and co-payment**
- No income eligibility requirement

For more information, visit www.amgenassist.com/copay or call 1-866-AMG-ASST (1-866-264-2778), Monday–Friday, 9:00 AM to 8:00 PM EST

*\$25 out-of-pocket cost for each dose of Prolia® (denosumab) and EVENITY® (romosozumab-aqqg) through Amgen SupportPlus.

**Terms conditions and program maximums apply. Other restrictions may apply. See the Amgen SupportPlus Co-Pay Program Terms and Conditions for details. This program is not open to patients receiving prescription reimbursement under any federal state or government-funded healthcare program. Not valid where prohibited by law.

Government insurance (like Medicare)

Amgen Assist 360™ can refer you to independent, nonprofit patient assistance programs that may be able to help you afford your LUMAKRAS® co-pay costs.†

Amgen Assist 360™ is here to help. Contact us at 1-888-427-7478.

†Program eligibility is based on the nonprofit's criteria. Amgen has no control over these programs and provides referrals as a courtesy only.

Uninsured or under-insured

AMGEN® Safety Net Foundation Serving Patients in Need™

Amgen Safety Net Foundation is a nonprofit patient assistance program sponsored by Amgen. It helps qualifying people access Amgen medicines at no cost.

Visit the Amgen Safety Net Foundation

www.amgensafetynetfoundation.com

ONCE-DAILY ORAL

LUMAKRAS®
(sotorasib) 120 mg tablets
320 mg tablets

Where can I get LUMAKRAS®?

There are multiple ways to receive your LUMAKRAS® treatment. Talk to your doctor about options for you.

LUMAKRAS® may be available through a specialty pharmacy. Your doctor can help you find a specialty pharmacy that works with your insurance.

Working with a specialty pharmacy: Once your insurance coverage has been verified, the specialty pharmacy will contact you to set up delivery of your prescription.

Specialty pharmacy providers may be able to help you with the following⁹:



Fill your prescription
and coordinate home delivery



Connect you to
additional support services



Help you navigate
your insurance coverage



Answer questions
about paying for your treatment

Where can I go to connect with people living with NSCLC like me?


The KRAS G12C community is here for you. There are many lung cancer organizations and patient communities that can provide you with useful information and offer you and your caregiver much-needed support. We've included a few examples of independent, nonprofit organizations that may be able to help people with NSCLC.

Please note that the following advocacy organizations don't endorse any specific cancer treatments. You should talk with your doctor about what treatment is right for you.

Connect with communities to help you stay informed and supported.



The above are examples of independent, nonprofit organizations that may provide useful information and resources. Amgen has no control over these programs and provides information as a courtesy only.



Notes

You can use this space to write down the questions you'd like to discuss with your doctor, or other important information.

References: **1.** LUMAKRAS® (sotorasib) Patient Information. Amgen. **2.** LUMAKRAS® (sotorasib) Prescribing Information. Amgen. **3.** NCI Dictionary of Cancer Terms. Cancer.gov. Accessed on January 23, 2023. **4.** Ryan MB, Corcoran RB, *Nat Rev Clin Oncol.* 2018;15:709-710. **5.** Data on file, Amgen. [Analysis of AACR Genie v12-2022]. **6.** Hong DS, et al. *N Engl J Med.* 2020;383:1208. **7.** Kalemkerian GP, et al. *J Clin Oncol.* 2018;36:913. **8.** NCI Biomarker Testing for Cancer Treatment. Cancer.gov. Accessed on January 25, 2023. **9.** National Association of Specialty Pharmacies. Napsnet.org. Accessed on January 31, 2023.



Important Safety Information

What should I tell my healthcare provider before taking LUMAKRAS®?

- Before taking LUMAKRAS®, tell your healthcare provider about all your medical conditions, including if you:
 - have liver problems.
 - have lung or breathing problems other than lung cancer.
 - are pregnant or plan to become pregnant. It is not known if LUMAKRAS® will harm your unborn baby.
 - are breastfeeding or plan to breastfeed. It is not known if LUMAKRAS® passes into your breast milk. Do not breastfeed during treatment with LUMAKRAS® and for 1 week after the last dose.
- Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, dietary and herbal supplements. LUMAKRAS® can affect the way some other medicines work, and some other medicines can affect the way LUMAKRAS® works.
- Especially tell your healthcare provider if you take antacid medicines, including Proton Pump Inhibitor (PPI) medicines or H₂ blockers during treatment with LUMAKRAS®. Ask your healthcare provider if you are not sure.

LUMAKRAS® may cause serious side effects, including:

- Liver Problems: LUMAKRAS® may cause abnormal liver blood test results. Your healthcare provider should do blood tests before starting and during treatment with LUMAKRAS® to check your liver function. Tell your healthcare provider right away if you get any signs or symptoms of liver problems, including: your skin or the white part of your eyes turns yellow (jaundice), dark or “tea-colored” urine, light-colored stools (bowel movements), tiredness or weakness, nausea or vomiting, bleeding or bruising, loss of appetite, and pain, aching, or tenderness on the right side of your stomach-area (abdomen).
- Lung or breathing problems: LUMAKRAS® may cause inflammation of the lungs that can lead to death. Tell your healthcare provider or get emergency medical help right away if you have new or worsening shortness of breath, cough, or fever.
- Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with LUMAKRAS® if you develop side effects.

The most common side effects

- The most common side effects of LUMAKRAS® include diarrhea, muscle or bone pain, nausea, tiredness, liver problems, cough, changes in liver function tests, and changes in certain .
- These are not all the possible side effects of LUMAKRAS®. Call your doctor for medical advice about side effects.

Please click [here](#) to see LUMAKRAS® full Prescribing Information.